Fig. 2

PTPN2 inhibits TG-initiated ERS through IRE1-XBP1 and PERK/EIF2α/ATF-4 pathways in TNBC. (A & B) The bar graph shows that ectopic expression of PTPN2 45 kDa or PTPN2 48 kDa inhibits expression of key molecules in IRE1 and PERK pathways in TG-treated MDA-MB-231 (A) and SUM159 (B) cells by qPCR. All experiments were conducted three times independently (n = 3). (C) The Western blot shows that ectopic expression of PTPN2 45 kDa or PTPN2 48 kDa inhibits expression of key molecules in IRE1 and PERK pathways in TG-treated MDA-MB-231 and SUM159 cells. PTPN2 serves to indicate over-expression of PTPN2, and GAPDH serves as a loading control. All experiments were conducted two times independently (n = 2). (D & E) The bar graph shows that knockdown of PTPN2 augments expression of key molecules in IRE1 and PERK pathways in TG-treated MDA-MB-231 (D) and SUM159 (E) cells by qPCR. All experiments were conducted three times independently (n = 3). (F) The Western blot shows that knockdown of PTPN2 augments expression of key molecules in IRE1 and PERK pathways in TG-treated MDA-MB-231 and SUM159 cells. PTPN2 serves to indicate knockdown of PTPN2, and GAPDH serves as a loading control. All experiments were conducted two times independently (n = 2).